Aurinia Pharma

Forecast & Rating7 analysts currently cover Aurinia Pharma, with about 57.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $17.00, about 13.6% upside from the current price of $14.96. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 46.7% of past price targets were eventually met, which adds credibility. For you, this means institutional views on Aurinia Pharma are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Jul 20, 2026; for reference only and not investment advice.